ClinicalTrials.gg
WithdrawnNCT06297200Updated Nov 9, 2026

Low-Intensity Focused Ultrasound and the Complex Patient

An interventional study of Low-Intensity Focused Ultrasound and Low-Intensity Focused Ultrasound - sham in Opioid Use Disorder, Chronic Pain and Anxiety Disorder, sponsored by Virginia Polytechnic Institute and State University. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Virginia Polytechnic Institute and State University · Not applicable, Interventional, and Basic science

How we know

Why this study was withdrawn
Unable to recruit any eligible participants.
Updated Nov 9, 2026Now WithdrawnEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 1,223 studies in Opioid-Related Disorders with a site in United States — 246 open to participants now, 316 under way, 18 of them phase 3. Opioid-Related Disorders · United States.

Enrollment
1,005th of 1,098
0 · median 56
Started
2024
with 86 others
No phase
571 of 1,223
133 open now
Registered
983rd of 1,223
by date

Among the 1,223 studies in Opioid-Related Disorders with a site in United States, this one is the 1,005th largest by enrollment of the 1,098 interventional ones that give a count, is one of 87 that started in 2024, is one of 571 with no phase, and was the 983rd registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

246 of the 1,223 studies in Opioid-Related Disorders with a site in United States are open now. Recruiting first, the newest first:

241 more — sign in →

All 246 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,223 studies in Opioid-Related Disorders with a site in United States, or all of them as a file.
02

Study summary

Studying the effects of Low Intensity Focused Ultrasound (LIFU) on measures of pain, craving, and anxiety in a complex patient population.

03

Conditions studied

  • Opioid Use Disorder
  • Chronic Pain
  • Anxiety Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females aged 18-65 years
  2. Current diagnosis of Chronic Back Pain as defined by pain duration of at least three months, with back pain being an ongoing problem for at least half the days of the last six months.
  3. Have evidence of central sensitization (CS) as measured by the Widespread Pain/Symptom Severity Index (WPSSI) with a score of Widespread Pain Index (WPI) ≥ 7 and Symptom Severity (SS) ≥ 5 or WPI = 3-6 and SS ≥ 9.
  4. Meet the , Fifth Edition (DSM-5) criteria for current opiate use disorder as diagnosed by the Structured Clinical Interview for DSM-5.
  5. Be in treatment for opioid use disorder (OUD) including buprenorphine or methadone.
  6. Meet the DSM-5 criteria for a current anxiety disorder: generalized anxiety disorder, post-traumatic stress disorder or social anxiety disorder as diagnosed by the Structured Clinical Interview for DSM-5.

Exclusion criteria

Exclusion Criteria:

  1. Evidence of neuropathic pain
  2. Previous spine surgery
  3. Current substance use disorder other than OUD or tobacco use disorder
  4. Current diagnosis of schizophrenia or schizo-affective disorder
  5. Chronic Pain Conditions other than chronic back pain
  6. Daily opiate use other than buprenorphine/methadone for OUD/pain control
  7. Pregnant or breastfeeding
  8. History of head injury, seizures, neurologic disorders including cerebrovascular disease, stroke, brain surgery, brain tumor, multiple sclerosis, or neurodegenerative diseases
  9. History of metastasizing cancers, inflammatory disorder (rheumatoid arthritis, polymyalgia rheumatica, scleroderma, lupus or polymyositis), unintended weight loss of 20 pounds or more in the last year, or cauda equina syndrome
  10. Ferromagnetic implants or other for magnetic resonance imaging (MRI)
  11. Evidence of arteriovenous malformation, aneurysm, infarct, meningioma, parenchymal brain tumor or evidence of neurodegenerative processes and/or white matter lesions greater than that expected for age as determined by the study neuroradiologist
  12. Unstable medical conditions such as congestive heart failure, unstable angina, poorly controlled arrhythmia active system infection end stage renal disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Pain, Craving, and Anxiety measures

    Multi visit - LIFU/Sham. Participants will complete pain, craving, and anxiety measures pre and post intervention.

    Device: Low-Intensity Focused Ultrasound · Device: Low-Intensity Focused Ultrasound - sham

Interventions

  • DeviceLow-Intensity Focused Ultrasound

    A noninvasive brain stimulation device using low-intensity focused ultrasound (LIFU) - ultrasound will be used to test whether noninvasive brain stimulation can effect pain, craving, and anxiety.

  • DeviceLow-Intensity Focused Ultrasound - sham

    A sham condition that will mimic the application of LIFU without actually administering any ultrasound to the brain.

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events via a neurological examination

    Any abnormal finding from the neurological exam will be recorded as an adverse event (AE) and tabulated with the side effects and tolerability data.

    Time frame: Assessed per participant, over the course of participation - an average of 4 weeks

  2. Incidence of Treatment-Emergent Adverse Events via a side effects questionnaire

    Side effects and reported severity will be tabulated and summarized on a 5 point likert scale.

    Time frame: Assessed per participant, over the course of participation - an average of 4 weeks

  3. Changes in Heart Rate (HR)

    changes in HR compared pre/post LIFU and at follow up

    Time frame: Assessed per participant, over the course of participation - an average of 4 weeks

  4. Changes in Respiration Rate (RR)

    changes in RR compared pre/post LIFU and at follow up

    Time frame: Assessed per participant, over the course of participation - an average of 4 weeks

  5. Changes in mood via visual analog mood scale (VAMS) such as the wong-baker face scale.

    changes in mood scale compared pre/post LIFU and at follow up

    Time frame: Assessed per participant, over the course of participation - an average of 4 weeks

  6. Changes in Blood Pressure (BP)

    changes in BP (systolic and diastolic) compared pre/post LIFU and at follow up

    Time frame: Assessed per participant, over the course of participation - an average of 4 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2024 to primary completion in Oct 2026, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2024
First posted
Mar 7, 2024
StartActual
Dec 4, 2024
Primary completionActual
Oct 31, 2026
CompletionActual
Oct 31, 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Withdrawn Unable to recruit any eligible participants.
changed Nov 9, 2026
Enrollment
25 (estimated)→0 (actual)
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Recruiting→Withdrawn
    Why stopped Unable to recruit any eligible participants.
    Enrollment 25 (estimated)→0 (actual)
    + 4 other changes: verification date, date precision, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06297200
Collaborators
Salem VA Medical Center, Washington DC VA Medical Center
Responsible party
Wynn Legon (Assistant Professor, Virginia Polytechnic Institute and State University) — Principal investigator
First posted
Mar 7, 2024
Start date
Dec 4, 2024
Primary completion
Oct 31, 2026
Completion
Oct 31, 2026
Last update
Nov 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion